Showing 1561-1570 of 2314 results for "".
- Visus Therapeutics Appoints Eric D. Donnenfeld, MD, to Board of Directorshttps://modernod.com/news/visus-therapeutics-appoints-eric-d-donnenfeld-md-to-board-of-directors/2481347/Visus Therapeutics announced the appointment of Eric D. Donnenfeld, MD, to the company’s Board of Directors. Dr. Donnenfeld brings more than 30 years of clinical experience as an internationally recognized expert in refractive, cornea, and cataract surgery. “I am thrill
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)https://modernod.com/news/viridian-announces-positive-data-from-ongoing-phase-12-trial-evaluating-low-dose-vrdn-001-in-patients-with-thyroid-eye-disease-ted/2481334/Viridian Therapeutics announced positive topline clinical data from the third, low dose cohort in its ongoing phase 1/2 clinical trial of VRDN-001, an anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). The company said it believes
- Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy FT-001 for the Treatment of Leber Congenital Amaurosis-2https://modernod.com/news/frontera-therapeutics-doses-first-patient-in-phase-1-clinical-trial-for-gene-therapy-ft-001-for-the-treatment-of-leber-congenital-amaurosis-2/2481327/Frontera Therapeutics announced that it has dosed the first patient in a phase 1 clinical trial of its lead gene therapy program, FT-001, for the treatment of Leber Congenital Amaurosis-2, a severe inherited retinal disease related to a mutation in the RPE65 gene. FT-001 is administered by a
- AOA Survey: Doctors of Optometry Embrace Myopia Managementhttps://modernod.com/news/aoa-survey-doctors-of-optometry-embrace-myopia-management/2481277/A new AOA survey of doctors of optometry presents a snapsho
- Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosahttps://modernod.com/news/kiora-pharmaceuticals-doses-first-patient-in-abacus-phase-1b-study-evaluating-kio-301-for-retinitis-pigmentosa/2481248/Kiora Pharmaceuticals announced the dosing of the first patient in a first-in-human open-label clinical trial for KIO-301, intended to restore vision loss in patients with retinitis pigmentosa (RP). "We are thrilled the first patient has been treated and I'm very enc
- DORC Acquires Peregrine Surgical and Completes Acquisition of the Remaining Stake in WEFIShttps://modernod.com/news/dorc-acquires-peregrine-surgical-and-completes-acquisition-of-the-remaining-stake-in-wefis/2481192/DORC announced the acquisition of Peregrine Surgical and the acquisition of the full ownership of WEFIS GmbH following an initial equity investment announced earlier in 2022. Financial terms of the deals were not disclosed. DORC says both acquisitions extend the productio
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-pavia-trial-of-eyp-1901-for-the-treatment-of-non-proliferative-diabetic-retinopathy/2481131/EyePoint Pharmaceuticals announced that the first patient has been dosed in the phase 2 PAVIA clinical trial of EYP-1901, a potential sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting non-proliferative diabetic retinopathy (NPDR).
- Neurophth Announces First Patient Dosed in Phase 3 Clinical Trial for the Gene Therapy Treatment of LHONhttps://modernod.com/news/neurophth-announces-first-patient-dosed-in-phase-3-clinical-trial-for-the-gene-therapy-treatment-of-lhon/2481126/Neurophth Therapeutics announced that the first patient has been dosed in phase 3 clinical trial for the treatment of Leber hereditary optic neuropathy (LHON). Neurophth is conducting a phase 1/2/3, multicenter, two-part study aimed at evaluating the safety, tolerability, and effic
- Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-first-subject-dosed-with-ixo-vec-in-the-phase-2-luna-trial-for-the-treatment-of-wet-amd/2481097/Adverum Biotechnologies announced that the first subject was dosed in the LUNA phase 2 trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet (AMD). “Dosing the first subject in the phase 2 LUNA study brings us a step cl
- Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and Wet AMD for 12- and 16-Week Dosinghttps://modernod.com/news/aflibercept-8-mg-meets-primary-endpoints-in-two-global-pivotal-trials-for-dme-and-wet-amd-for-12-and-16-week-dosing/2481071/Regeneron Pharmaceuticals announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The PHOTON trial in DME and the PUL